Background
Phase 3, open-label, randomized controlled trial (CLL8; German CLL Study Group). N=817 patients with previously untreated CLL (Binet B/C or symptomatic A), all eligible for fludarabine-based therapy. Del(17p) patients were included. Randomized 1:1. Median age 61 years. First trial to demonstrate a survival benefit for adding rituximab to chemotherapy in CLL.
Interventions and follow up
Arm A: FCR: fludarabine 25 mg/m² IV days 1–3 + cyclophosphamide 250 mg/m² IV days 1–3 + rituximab 375 mg/m² day 1 cycle 1, then 500 mg/m² day 1 cycles 2–6; 6 cycles q28d
Arm B: FC: fludarabine 25 mg/m² IV days 1–3 + cyclophosphamide 250 mg/m² IV days 1–3; 6 cycles q28d
Primary endpoint: Progression-free survival (PFS)
Median follow up: 37.7 months (primary); 5.9 years (Fischer Blood 2016 long-term)
Arm B: FC: fludarabine 25 mg/m² IV days 1–3 + cyclophosphamide 250 mg/m² IV days 1–3; 6 cycles q28d
Primary endpoint: Progression-free survival (PFS)
Median follow up: 37.7 months (primary); 5.9 years (Fischer Blood 2016 long-term)
Results
Median PFS: 51.8 vs 32.8 months (FCR vs FC), HR 0.56 (95% CI 0.46–0.69), P<.001
ORR: 95.1% vs 88.4%
CR: 44.5% vs 22.9% (P<.001)
MRD-negative (bone marrow): 71% vs 41%
OS (5.9-yr, Fischer 2016): HR 0.67 (95% CI 0.48–0.92), P=.0001; 5-yr OS 79.9% vs 73.5%
ORR: 95.1% vs 88.4%
CR: 44.5% vs 22.9% (P<.001)
MRD-negative (bone marrow): 71% vs 41%
OS (5.9-yr, Fischer 2016): HR 0.67 (95% CI 0.48–0.92), P=.0001; 5-yr OS 79.9% vs 73.5%
Adverse events
Hematologic: Grade ≥3 neutropenia 34% (FCR) vs 21% (FC); grade ≥3 anemia and thrombocytopenia <5% in both arms.
Infections: Grade ≥3 infections 25.7% vs 17.6%.
Infusion reactions: Any grade 66% (cycle 1), rituximab-associated.
Secondary malignancy: Secondary MDS/AML 0.5% (FCR) vs 0.3% (FC); dose reduction or delay 26% vs 22%.
Infections: Grade ≥3 infections 25.7% vs 17.6%.
Infusion reactions: Any grade 66% (cycle 1), rituximab-associated.
Secondary malignancy: Secondary MDS/AML 0.5% (FCR) vs 0.3% (FC); dose reduction or delay 26% vs 22%.
Conclusions
FCR significantly improved PFS, CR rates, and MRD negativity compared with FC in treatment-naive CLL, and a subsequent long-term analysis demonstrated an OS benefit. FCR established the standard of care for fit, treatment-naive CLL patients and remains the benchmark against which targeted therapies are compared.
Key Limitations
Benefits were predominantly seen in IGHV-mutated CLL, in whom FCR produces long-term remissions approaching functional cure; IGHV-unmutated patients had shorter remissions and higher relapse. Del(17p)/TP53-mutated patients had poor outcomes and FCR is now contraindicated in this setting. Higher grade ≥3 infection rates with FCR; cumulative immunosuppression and risk of secondary MDS/AML over time. Results not applicable to older or unfit patients (median age 61, CIRS eligibility required).
Clinical Context
FCR remains a preferred chemoimmunotherapy option for young (≤65 years), fit patients with IGHV-mutated CLL without del(17p)/TP53 mutation where functional cure is achievable. ECOG E1912 demonstrated ibrutinib+rituximab superior in PFS and OS vs FCR in unselected fit patients, and FLAIR showed ibrutinib+venetoclax superior to FCR. FCR remains favored for IGHV-mutated patients ≤65 who prefer time-limited treatment. ESMO-MCBS: 5 (approved indication).